Putting the Alzheimer's cognitive test to the test I: Traditional psychometric methods

Alzheimer's and Dementia

Volumn 9, Issue 1 SUPPL., 2013, Pages

  Hobart, Jeremy ^a   Cano, Stefan ^a   Posner, Holly ^b   Selnes, Ola ^c   Stern, Yaakov ^d   Thomas, Ronald ^e   Zajicek, John ^a,e  

^a PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

^b PFIZER INC   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Clinical trials; Psychometrics; Reliability; Validity

Indexed keywords

AD NEUROIMAGING INITIATIVE; ADULT; AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ALZHEIMER DISEASE ASSESSMENT SCALE COGNITIVE BEHAVIOR SECTION; ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL RESEARCH; COGNITION; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOMETRY; RASCH MEASUREMENT THEORY; RATING SCALE; SENSITIVITY AND SPECIFICITY;

EID: 84873404322     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2012.08.006     Document Type: Article

References (13)

1. K. Blennow, M. de Leon, and H. Zetterberg Alzheimer's disease Lancet 368 2006 387 403
2. R. Brookmeyer, E. Johnson, K. Ziegler-Graham, and H.M. Arrighi Forecasting the global burden of Alzheimer's disease Alzheimers Dement 3 2007 186 191
3. Alzheimer's Association Alzheimer's disease facts and figures 2008 Alzheimer's Association Chicago
4. P. Aisen, K. Schafer, M. Grundman, E. Pfeiffer, M. Sano, and K. Davis Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: A randomized controlled trial JAMA 289 2003 2819 2826
5. K. Mohs, W. Rosen, and K. Davis The Alzheimer's Disease Assessment Scale: An instrument for assessing treatment efficacy Psychopharmacol Bull 19 1983 448 450
6. M. Dichgans, H. Markus, S. Salloway, A. Verkkoniemi, M. Moline, and Q. Wang Donepezil in patients with subcortical vascular cognitive impairment: A randomised double-blind trial in CADASIL Lancet Neurol 7 2008 310 318
7. S. Cano, H. Posner, M. Moline, S. Hurt, J. Swartz, and T. Hsu The ADAS-cog in Alzheimer's disease clinical trials: Psychometric evaluation of the sum and its parts J Neurol Neurosurg Psychiatry 81 2010 1363 1368
8. G. Weyer, H. Erzigkeit, S. Kanowski, R. Ihl, and D. Hadler Alzheimer's Disease Assessment Scale: Reliability and validity in a multicenter clinical trial Int Psychogeriatr 9 1997 123 138
9. P. Doraiswamy, L. Kaiser, F. Bieber, and R. Garman The Alzheimer's Disease Assessment Scale: Evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease Alzheimer Dis Assoc Disord 15 2001 174 183
10. U.S. Food and Drug Administration. Patient reported outcome measures: Use in medical product development to support labelling claims. Available at: www.fda.gov/cber/gdlns/prolbl.pdf. Accessed April 12, 2012.
11. J. Hobart, S. Cano, and A. Thompson Effect sizes can be misleading: Is it time to change the way we measure change? J Neurol Neurosurg Psychiatry 81 2010 1044 1048
12. J. Hobart, S. Cano, J. Zajicek, and A. Thompson Rating scales as outcome measures for clinical trials in neurology: Problems, solutions, and recommendations Lancet Neurol 6 2007 1094 1105
13. D. Andrich Rating scales and Rasch measurement Expert Rev Pharmacoecon Outcome Res 11 2011 571 585